Search

Your search keyword '"Zhang, Lingjian"' showing total 133 results
Start Over Author "Zhang, Lingjian" Publication Year Range Last 50 years
133 results on '"Zhang, Lingjian"'

6. Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance

Author

Zhou, Diwenxin, primary, Zhao, Shuai, additional, He, Keting, additional, Liu, Qiuhong, additional, Zhang, Fen, additional, Pu, Zhangya, additional, Xiao, Lanlan, additional, Zhang, Lingjian, additional, Chen, Shangci, additional, Qian, Xiaohan, additional, Wu, Xiaoxin, additional, Shen, Yangfan, additional, Yu, Ling, additional, Zhang, Huafen, additional, Jin, Jiandi, additional, Xu, Min, additional, Wang, Xiaoyan, additional, Zhu, Danhua, additional, Xie, Zhongyang, additional, and Xu, Xiaowei, additional

Published
2024
Full Text
View/download PDF

10. CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis.

Author

Zhu, Huihui, Liu, Qiuhong, Meng, Qinna, Zhang, Lingjian, Ju, Siwei, Lang, Jiaheng, Zhu, Danhua, Chen, Yongxia, Aishan, Nadire, Ouyang, Xiaoxi, Zhang, Sainan, Jin, Lidan, Xiao, Lanlan, Wang, Linbo, Li, Lanjuan, and Ji, Feiyang

Subjects
DRUG resistance in cancer cells, POST-translational modification, MOLECULAR chaperones, TRANSFERRIN receptors, SORAFENIB, PROTEIN receptors
Abstract

Sorafenib is widely used in treating advanced hepatocellular carcinoma (HCC). However, its effectiveness in prolonging patient survival is limited by the development of drug resistance. To systematically investigate the resistance mechanisms of Sorafenib, an integrative analysis combining posttranslational modification (PTM) omics and CRISPR/Cas9 knockout library screening was conducted. This analysis identified ubiquitination at lysine 21 (K21) on chaperonin-containing TCP1 subunit 3 (CCT3) as being associated with Sorafenib resistance. Transcriptomic data from HCC patients treated with Sorafenib revealed that CCT3 expression was lower in responders compared to non-responders. Experimentally, inhibiting the expression of CCT3 sensitized HCC cells to Sorafenib and enhanced Sorafenib-induced ferroptosis. Additionally, CCT3 was found to interact with ACTN4, hindering the recycling of transferrin receptor protein 1 (TFRC) to the cell membrane, thus obstructing iron endocytosis. Mechanistically, the inhibition of ferroptosis by CCT3 depends on the deubiquitination of K6-linked non-degradative ubiquitination at its K21, which occurs upon Sorafenib treatment. Moreover, CCT3 knockdown enhanced the anti-tumor effects of Sorafenib in nude mice. In summary, we have identified a novel function of the chaperone protein. Targeting the CCT3/ACTN4/TFRC axis offers a promising strategy to enhance ferroptosis and overcome Sorafenib resistance in HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Branched-Chain Amino Acids in Liver Diseases: Complexity and Controversy.

Author

Zhang, Yaqi, Zhan, Luqi, Zhang, Lingjian, Shi, Qingmiao, and Li, Lanjuan

Abstract

Branched-chain amino acids (BCAAs), as essential amino acids, engage in various physiological processes, such as protein synthesis, energy supply, and cellular signaling. The liver is a crucial site for BCAA metabolism, linking the changes in BCAA homeostasis with the pathogenesis of a variety of liver diseases and their complications. Peripheral circulating BCAA levels show complex trends in different liver diseases. This review delineates the alterations of BCAAs in conditions including non-alcoholic fatty liver disease, hepatocellular carcinoma, cirrhosis, hepatic encephalopathy, hepatitis C virus infection, and acute liver failure, as well as the potential mechanisms underlying these changes. A significant amount of clinical research has utilized BCAA supplements in the treatment of patients with cirrhosis and liver cancer. However, the efficacy of BCAA supplementation in clinical practice remains uncertain and controversial due to the heterogeneity of studies. This review delves into the complicated relationship between BCAAs and liver diseases and tries to untangle what role BCAAs play in the occurrence, development, and outcomes of liver diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Cu2SnTe3 Nanoparticles for Chemodynamic/Photodynamic /Photothermal Combination Tumor Therapy.

Author

Gao, Nan, Huang, Qiushi, Zhang, Lingjian, Gao, Mengluan, Chen, Yusheng, and Zou, Rujia

Subjects
PHOTOTHERMAL effect, PHOTOTHERMAL conversion, PHOTODYNAMIC therapy, ELECTRON pairs, TUMOR treatment, NANOPARTICLES
Abstract

Cancer is a serious threat to human life. However, the effect of single treatment method is limited at present. Here, a Cu2SnTe3 (CST) nano‐reagent which can provide a strong synergetic effect in tumor therapy is successfully constructed. CST nanoparticles can not only convert endogenous H2O2 into ∙OH through surface‐catalyzed reactions, but also generate 1O2 based on light irradiation‐induced electron pair separation, leading to excessive oxidative stress accumulation in tumor cells. Interestingly, CST nanoparticles are also found to possess catalase‐like activity, which enhances the level of O2 within hypoxic tumors, further improving the production efficiency of 1O2 by photodynamic therapy (PDT). In addition, the CST nanoparticles exhibit good photothermal conversion, which facilitates to promote more ∙OH production by chemodynamic therapy (CDT). The results of in vitro and in vivo anti‐tumor experiments both demonstrate that CST nanoparticles can effectively inhibit the growth of tumor with minimal side effects. To sum up, CST nanoparticles have great potential in tumor treatment for efficient synergetic CDT/PDT/photothermal therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Additional file 2 of SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

Author

Hu, Qingqing, Liu, Qiuhong, Zhao, Yalei, Zhang, Lingjian, and Li, Lanjuan

Abstract

Additional file 2: Fig. S1. High expression of SGOL2 in HCC in public database. Fig. S2. The mRNA and protein levels of SGOL1 after the knockdown of SGOL2 in HCC cell lines. Fig. S3. Subgroup expression analysis of SGOL2 in HCC. Fig. S4. Elevated expression of SGOL2 indicated a poor prognosis in HCC patients. Fig. S5. SGOL2 mutations and the associations between SGOL2 and immune cells in HCC. Fig. S6. Genes related to SGOL2 or MAD2 in HCC. Fig. S7. Hub gene analysis. Fig. S8. The predicted transcription factors binding to SGOL2 or MAD2.

Published
2022
Full Text
View/download PDF

34. Correction: Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance.

Author

Zhou, Diwenxin, Zhao, Shuai, He, Keting, Liu, Qiuhong, Zhang, Fen, Pu, Zhangya, Xiao, Lanlan, Zhang, Lingjian, Chen, Shangci, Qian, Xiaohan, Wu, Xiaoxin, Shen, Yangfan, Yu, Ling, Zhang, Huafen, Jin, Jiandi, Xu, Min, Wang, Xiaoyan, Zhu, Danhua, Xie, Zhongyang, and Xu, Xiaowei

Subjects
MONONUCLEAR leukocytes, AFFILIATION (Psychology), COMMUNICABLE diseases, CLINICAL pathology, COVID-19
Abstract

This document is a correction notice for an article titled "Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance." The correction involves updating the first affiliation of the authors to the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, in Hangzhou, China. The original article has been corrected, and the publisher remains neutral regarding jurisdictional claims and institutional affiliations. [Extracted from the article]

Published
2024
Full Text
View/download PDF

42. Aneurysm and Artery Dissection Following the use of Vascular Endothelial Growth Factor Inhibitor: A Real-World Analysis Using a Spontaneous Reporting System

Author

Jian Gong, WANG Shuyue, CHEN Mingzhu, ZHANG Xinghui, ZHANG Lingjian, JIA Min, SHEN Zhiwen, WANG Junyan, XU Jing, ZHENG Zheng, WANG Mengmeng, LV Xuanrui, ZONG Xiaoyu, LI Hui, ZHOU Jin, MENG Tong, Bin Zhao, and GONG Jian

Abstract

Background: There are few real-world studies comparing the incidence, clinical features, and prognosis of aneurysm and artery dissection related to various vascular endothelial growth factor inhibitor (VPI) regimens. This study evaluated the recent evidence of aneurysm and artery dissection after VPI therapy. The purpose was to evaluate and compare the links between different VPIs and aneurysm and artery dissection by investigating the Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: Using FAERS data from January 2004 to March 2020, disproportionality analysis was used for data mining to screen suspected aneurysm and artery dissection cases after different VPI treatments. The times to onset and fatality rates of suspected drugs were also investigated to assess prognoses.Results: In total, there were 634 reports of aneurysm and artery dissection events after VPI. Ramucirumab appeared to have a stronger association than other VPIs, based on the reporting odds ratio (ROR = 3.68, 95% [2.18, 6.23]). The results showed a significant difference in onset time (P < 0.001), and a quick onset occurred in 60.13% of cases. The median time to aneurysm and artery dissection was 79.5 (IQR: 19–273.5) days after VPI administration. The results also showed that men were more affected than women (59.68% vs. 40.32%), and patients older than 45 years were more affected than younger patients (68.12% vs. 3.93%). Finally, the suspected drugs generally led to a 19.98% fatality rate and a 29.81% hospitalization rate. The highest death rate was associated with Aflibercept (25.49%).Conclusions: We identified signals for aneurysm and artery dissection following various VPIs in real-world practice using the FAERS, which represents the first step for continued pharmacovigilance investigation.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results